Bioretec Oy Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Alan Donze

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	1.3yrs
Durata media del Consiglio di amministrazione	1.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Alan Donze (59 yo)

less than a year

Mandato

Mr. Alan Donze is Chief Executive Officer of Bioretec Oy from May 20, 2024. Mr. Donze has held senior leadership positions for a number of other medical device and technology companies including Smith Neph...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Alan Donze	Chief Executive Officer	less than a year	Nessun dato	Nessun dato
Johanna Salko	Chief Financial Officer	3.8yrs	Nessun dato	Nessun dato
Esa Hallinen	Director of Operations	1.3yrs	Nessun dato	Nessun dato
Timo Lehtonen	Chief Technology Officer	less than a year	Nessun dato	Nessun dato
Rami Ojala	Sales & Marketing Director	2.8yrs	Nessun dato	Nessun dato

1.3yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di 0TN non è considerato esperto (durata media 1.3 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Tomi Numminen	Chairman of the Board	8.5yrs	Nessun dato	Nessun dato
Kustaa Poutiainen	Director	1.5yrs	Nessun dato	Nessun dato
Sarah Van Hellenberg Hubar-Fisher	Director	3.6yrs	Nessun dato	Nessun dato
Michael Piccirillo	Director	6.8yrs	Nessun dato	Nessun dato
Paivi Malinen	Director	2.6yrs	Nessun dato	Nessun dato
Klaus Dresing	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Fan Liu	Member of Scientific Advisory Board	1.7yrs	Nessun dato	Nessun dato
Theddy Slongo	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jeffrey Wang	Member of Scientific Advisory Board	1.7yrs	Nessun dato	Nessun dato
Richard Assaker	Member of Scientific Advisory Board	1.7yrs	Nessun dato	Nessun dato
Stefan Rammelt	Member of Scientific Advisory Board	1.3yrs	Nessun dato	Nessun dato
Verena Schreiber	Member of Scientific Advisory Board	1.3yrs	Nessun dato	Nessun dato

1.7yrs

Durata media

53yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 0TN non è considerato esperto (durata media del mandato 1.7 anni), il che suggerisce un nuovo consiglio.

Bioretec Oy Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Bioretec Oy Shareholders' Nomination Board Appointed

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd Announces CEO Changes

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Recent updates

Bioretec Oy has filed a Follow-on Equity Offering in the amount of €5 million.

New minor risk - Share price stability

Bioretec Ltd. Updates Its Product Development Strategy by Accelerating the Product Development of RemeOs™? Spinal Interbody Cage

Bioretec Oy Shareholders' Nomination Board Appointed

Bioretec Ltd. Reports Successful Clinical Outcomes from U.S. Controlled Launch of RemeOs Trauma Screw

Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors

Bioretec Ltd. Receives a Patent by the U.S. Patent Office for its RemeOs Magnesium Alloy Composition

Bioretec Has Been Granted FDA Breakthrough Device Designation Status for its RemeOs Spinal Interbody Cage

Bioretec's European Market Authorization for RemeOs Trauma Screw Proceeded to Expert Panel Evaluation

Bioretec Oy to Report Q2, 2024 Results on Aug 15, 2024

Bioretec Ltd Announces CEO Changes

New minor risk - Share price stability

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Estimates the Approval of the European Market Authorization for the Biodegradable RemeOs™ Trauma Screw Will Move to the First Quarter of 2024

Bioretec Ltd Unveils Its Revitalized Scientific Advisory Board

Bioretec Oy Appoints Esa Hallinen as Director of Operations and Member of the Management Team

Bioretec Oy Approves Management Appointments

Bioretec Ltd Appoints Dr. Jeremy Dublon as Regulatory Advisor

No independent directors

Bioretec Ltd Submits Additional Information Requested by the FDA for US Registration of RemeOs Trauma Screws

Bioretec Oy to Report First Half, 2023 Results on Aug 11, 2023

No independent directors

Bioretec Ltd, Updates Estimate of U.S. registration of RemeOs™ Screws and Expects Approval in April 2023

Bioretec's Hybrid Composite Patent Has Been Approved in Europe

Bioretec Oy Announces ActivaPin Bioresorbable Implant Provides Good Alternative Treatment of Pediatric Elbow Injuries

Bioretec Ltd Announces Bioresorbable Activa IM-Nail™ Shows Convincing Results in Post-Market Clinical Follow Up Study for the Treatment of Children's Forearm Fractures

Bioretec Ltd Submits Market Authorization Request for Its Bioresorbable RemeOs™ Magnesium Screw in the U.S

No independent directors

Bioretec's ActivaPin(TM) Bioresorbable Implant Provides Excellent Clinical Outcome in the Treatment of Pediatric Wrist Fractures

Bioretec Oy Announces Appointment of Päivi Malinen as Member of the Board of Directors

No independent directors

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media